Revenue since approval for select cancer drugs 2017

This statistic shows the total revenue since approval for select cancer drugs that were on the market as of 2017. As of that year, Alexion Pharmaceuticals' drug Eculizumab generated a total revenue of nearly 13 billion U.S. dollars since the drug's approval in March 2007.

Total revenue since approval for select cancer drugs on the market as of 2017

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until March 31st
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

November 2017

Region

United States

Survey time period

as of November 2017

Supplementary notes

This statistic includes only pharmaceutical companies with a single oncologic drug approved by the Food and Drug Administration (FDA). Values are inflation adjusted for 2017 U.S. dollars.
* Alexion later had two drug approvals in the last quarter of 2015; these drugs are not included in this statistic.
** Compound acquired by the company on this date.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Oncology"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.